8 billion and non-GAAP diluted earnings per share from continuing operations of $0.

Segment revenue for the one fourth increased 30 % to $295 million, reflecting the contribution from solid generics programs, as well as acquisitions, which contributed 12 %age points to the segment profit growth in the one fourth. Solid performance under our branded manufacturer agreements was a positive driver also. Related StoriesCareFusion announces services to help improve medication safetyCareFusion third quarter revenue increases 9 percent to $919 millionNatus acquires CareFusion's Nicolet neurodiagnostic businessFor the full year, income for the Pharmaceutical Segment increased 4 % to $93.7 billion, and segment revenue increased 26 % to $1.3 billion.‘Rheumatologists nationwide welcome the development of biosimilars as an avenue for improving patient access to important biologic medications. However, we also want to make sure patient safety is at the forefront of the FDA's authorization process as biosimilars come to advertise,’ said CSRO President Dr. Michael Schweitz. ‘This study affirms that further guidance from FDA on important issues such as interchangeability and naming are needed before additional biosimilars are approved.’ Specific findings of the CSRO study include: A lot more than 82 % of respondents think that the U.S. Meals and Drug Administration approval criteria for designating a biosimilar as ‘interchangeable’ must be very rigorous to ensure patient safety; More than 75 % of rheumatologists surveyed say the FDA should mandate that biosimilars have got a different non-proprietary name compared to the innovator biologic medicine; Nearly 96 % of rheumatologists surveyed said the FDA should require labeling to identify a medication as a biosimilar and differentiate any important variations between it and the innovator biologic.